AR069120A1 - Usos de un inhibidor de glucoproteina vi (gpvi) - Google Patents
Usos de un inhibidor de glucoproteina vi (gpvi)Info
- Publication number
- AR069120A1 AR069120A1 ARP080104753A ARP080104753A AR069120A1 AR 069120 A1 AR069120 A1 AR 069120A1 AR P080104753 A ARP080104753 A AR P080104753A AR P080104753 A ARP080104753 A AR P080104753A AR 069120 A1 AR069120 A1 AR 069120A1
- Authority
- AR
- Argentina
- Prior art keywords
- fragment
- gpvi
- inhibitor
- active antibody
- peptide
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 229940122966 Glycoprotein inhibitor Drugs 0.000 abstract 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 abstract 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 abstract 1
- 206010061216 Infarction Diseases 0.000 abstract 1
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 abstract 1
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 210000004351 coronary vessel Anatomy 0.000 abstract 1
- 238000002283 elective surgery Methods 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Reivindicacion 1: Un método para inhibir el dano por reperfusion y/o infarto en un paciente que lo necesite caracterizado porque comprende administrar un inhibidor de glucoproteína de plaquetas VI (GPVI), en donde dicho inhibidor inhibe la interaccion entre GPVI plaquetaria y colágeno. Reivindicacion 5: El método de acuerdo con la reivindicacion 1, caracterizado porque el paciente requiere una cirugía electiva que resulte en el bloqueo temporario del flujo sanguíneo de la arteria coronaria. Reivindicacion 10: El método de acuerdo con la reivindicacion 6, caracterizado porque el anticuerpo comprende un fragmento de anticuerpo activo seleccionado un fragmento Fab producido en forma química, enzimática o recombinante, un fragmento F(ab)2, o un fragmento peptídico que comprende al menos una region determinante de complementariedad (CDR) específicos para un polipéptido GPVI, péptido, o su variante natural. Reivindicacion 11: El método de acuerdo con la reivindicacion 10, caracterizado porque el fragmento de anticuerpo activo es un fragmento de un anticuerpo seleccionado de OM1, OM2, OM3 y OM4. Reivindicacion 13: El método de acuerdo con la reivindicacion 10, caracterizado porque el fragmento de anticuerpo activo ha sido humanizado.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98433407P | 2007-10-31 | 2007-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069120A1 true AR069120A1 (es) | 2009-12-30 |
Family
ID=40591365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104753A AR069120A1 (es) | 2007-10-31 | 2008-10-30 | Usos de un inhibidor de glucoproteina vi (gpvi) |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100297116A1 (es) |
| EP (1) | EP2212416A4 (es) |
| JP (1) | JP2011502123A (es) |
| KR (1) | KR20100075585A (es) |
| CN (1) | CN101874107A (es) |
| AR (1) | AR069120A1 (es) |
| AU (1) | AU2008319336A1 (es) |
| BR (1) | BRPI0818807A2 (es) |
| CA (1) | CA2703770A1 (es) |
| IL (1) | IL205453A0 (es) |
| MX (1) | MX2010004537A (es) |
| RU (1) | RU2010121878A (es) |
| SG (1) | SG185307A1 (es) |
| TW (1) | TW200936606A (es) |
| WO (1) | WO2009058326A1 (es) |
| ZA (1) | ZA201002990B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852593B2 (en) * | 2009-12-18 | 2014-10-07 | Sanofi | Antagonist antibodies and their fab fragments against GPVI and uses thereof |
| EP2397495A1 (en) * | 2010-06-21 | 2011-12-21 | Sanofi | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
| EP2336188A1 (en) * | 2009-12-18 | 2011-06-22 | Sanofi-Aventis | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ302693B6 (cs) * | 1999-05-07 | 2011-09-07 | Aventis Pharma Deutschland Gmbh | Rekombinantní lidský glykoprotein VI, DNA, která ho kóduje a farmaceutický prostredek, který ho obsahuje |
| US20040001826A1 (en) * | 1999-06-30 | 2004-01-01 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
| AU7097400A (en) * | 1999-09-01 | 2001-03-26 | Otsuka Pharmaceutical Co., Ltd. | Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof |
| EP1224942A1 (en) * | 2001-01-23 | 2002-07-24 | Bernhard Dr. Nieswandt | Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases |
| GB0130543D0 (en) * | 2001-12-20 | 2002-02-06 | Univ Cambridge Tech | Human antibodies and their use |
| EP1369128A1 (en) * | 2002-06-07 | 2003-12-10 | Procorde GmbH | Inhibitors of glycoprotein VI and their therapeutic use |
| CA2532781A1 (en) * | 2003-07-18 | 2005-01-27 | Mochida Pharmaceutical Co., Ltd | The anti-platelet membrane glycoprotein vi monoclonal antibody |
| US7645592B2 (en) * | 2004-04-29 | 2010-01-12 | Otsuka Pharmaceutical Co., Ltd. | Glycoprotein VI antibodies and methods of use thereof |
| KR101194446B1 (ko) * | 2004-04-29 | 2012-10-24 | 오쓰까 세이야꾸 가부시키가이샤 | 당단백 ｖｉ에 특이적인 항체 및 그의 제조방법 |
| EP1876240B1 (en) * | 2005-04-28 | 2012-08-22 | Mochida Pharmaceutical Co., Ltd. | Anti-human platelet membrane glycoprotein vi monoclonal antibody |
-
2008
- 2008-10-29 KR KR1020107009550A patent/KR20100075585A/ko not_active Application Discontinuation
- 2008-10-29 JP JP2010531074A patent/JP2011502123A/ja active Pending
- 2008-10-29 CA CA2703770A patent/CA2703770A1/en not_active Abandoned
- 2008-10-29 WO PCT/US2008/012311 patent/WO2009058326A1/en active Application Filing
- 2008-10-29 EP EP08843804A patent/EP2212416A4/en not_active Withdrawn
- 2008-10-29 SG SG2012076709A patent/SG185307A1/en unknown
- 2008-10-29 MX MX2010004537A patent/MX2010004537A/es active IP Right Grant
- 2008-10-29 BR BRPI0818807-6A2A patent/BRPI0818807A2/pt not_active IP Right Cessation
- 2008-10-29 RU RU2010121878/15A patent/RU2010121878A/ru not_active Application Discontinuation
- 2008-10-29 AU AU2008319336A patent/AU2008319336A1/en not_active Abandoned
- 2008-10-29 CN CN200880114053A patent/CN101874107A/zh active Pending
- 2008-10-29 US US12/740,620 patent/US20100297116A1/en not_active Abandoned
- 2008-10-30 AR ARP080104753A patent/AR069120A1/es not_active Application Discontinuation
- 2008-10-31 TW TW097142069A patent/TW200936606A/zh unknown
-
2010
- 2010-04-29 ZA ZA2010/02990A patent/ZA201002990B/en unknown
- 2010-04-29 IL IL205453A patent/IL205453A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201002990B (en) | 2011-07-27 |
| CA2703770A1 (en) | 2009-05-07 |
| CN101874107A (zh) | 2010-10-27 |
| WO2009058326A1 (en) | 2009-05-07 |
| TW200936606A (en) | 2009-09-01 |
| JP2011502123A (ja) | 2011-01-20 |
| BRPI0818807A2 (pt) | 2014-10-29 |
| AU2008319336A1 (en) | 2009-05-07 |
| MX2010004537A (es) | 2010-05-20 |
| EP2212416A1 (en) | 2010-08-04 |
| RU2010121878A (ru) | 2011-12-10 |
| KR20100075585A (ko) | 2010-07-02 |
| SG185307A1 (en) | 2012-11-29 |
| IL205453A0 (en) | 2010-12-30 |
| US20100297116A1 (en) | 2010-11-25 |
| EP2212416A4 (en) | 2013-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Moura-da-Silva et al. | Jararhagin, a hemorrhagic snake venom metalloproteinase from Bothrops jararaca | |
| AR049978A1 (es) | Composicion farmaceutica que contiene neurotoxina botulinica | |
| UY30359A1 (es) | Coterapeutica para el tratamiento de epilepsia y trastornos relacionados i | |
| Gillespie et al. | Varicose veins possess greater quantities of MMP-1 than normal veins and demonstrate regional variation in MMP-1 and MMP-13 | |
| Masciantonio et al. | The balance between metalloproteinases and TIMPs: critical regulator of microvascular endothelial cell function in health and disease | |
| AR081450A1 (es) | Tratamiento de sarcoidosis usando celulas madre de placenta | |
| BRPI0921999B8 (pt) | uso de uma quantidade terapeuticamente eficaz de células tronco placentárias | |
| PE20120816A1 (es) | Composiciones que comprenden anticuerpos de dickkopf-1 | |
| PA8782201A1 (es) | Anticuerpo humanizados contra el globulómero ab(20-42) y sus usos | |
| NO20075400L (no) | Fremgangsmater, sammensetninger og formuleringer for a forebygge eller lindre ugunstige virkninger i en pasient | |
| CO6660439A2 (es) | Eliminación de serina proteasa por tratamiento con dióxido de silicona finamente dividido | |
| ECSP056187A (es) | Tratamiento con anticuerpos anti-vgf | |
| BR112012010252A2 (pt) | variantes de glicosilação de anticorpo | |
| PE20110802A1 (es) | Un anticuerpo antagonista de pcsk9 | |
| ATE499088T1 (de) | Glp-1-fc fusionsprotein-formulierung | |
| AR069806A1 (es) | Uso de un componente neurotoxico del complejo de toxina botulinica creada por la bacteria clostridium botulinum para reducir o evitar efectos colaterales | |
| EA200900920A1 (ru) | Соединения и композиции как ингибиторы активирующей канал протеазы | |
| BRPI0418277A (pt) | lenço úmido com baixa adição de lìquido | |
| AR069120A1 (es) | Usos de un inhibidor de glucoproteina vi (gpvi) | |
| ES2688030T3 (es) | Péptidos permeables celulares inhibidores de la ruta de transducción de la señal JNK para su uso en el tratamiento de enfermedades oculares inflamatorias | |
| MA35843B1 (fr) | Panneau de construction et sa fabrication | |
| PE20071368A1 (es) | Compuestos de ramnolipidos y metodos asociados de uso | |
| AR081928A1 (es) | Composicion de inmunoglobulinas humanas estabilizada | |
| MY157366A (en) | Therapies and compositions comprising cathepsin s antibodies | |
| BRPI0504199B8 (pt) | composições farmacêuticas baseadas em lopap e usos das ditas composições |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |